Abstract: A vaccine candidate is herein described comprised by statistically significant DNA fragments related to Civet SARS, Bat Sars, and BtRs BetaCov, BtRI BetaCov, and Neoromicia resulting in three types of compositions: 1) a composition of statistically significant DNA fragments, 2) a composition of RNA transcripts corresponding to the statistically significant DNA fragments, and 3) a computational reduction composition wherein the DNA fragments are fully or partially subtracted from a base organism, resulting in a synthetic organism which has a high statistical likelihood of problematic functions being partially or fully removed.

Abstract: A vaccine candidate is herein described comprised by statistically significant DNA fragments resulting in three types of compositions: 1) a composition of statistically significant DNA fragments, 2) a composition of RNA transcripts corresponding to the statistically significant DNA fragments, and 3) a computational reduction composition wherein the DNA fragments are fully or partially subtracted from a base organism, resulting in a synthetic organism which has a high statistical likelihood of problematic functions being partially or fully removed.

Abstract: A system for the rapid development of vaccines or anti-bacterial drugs is required when working with pandemics. The easiest way to formulate these new vaccines is through computational reduction of existing organisms via statistical models. Once vaccine candidates are arrived at through this method, “Super Organisms” containing all of the computationally reducible fragments can then be taken through a Crispr reduction process wherein those computationally reducible fragments are removed. The result is a vaccine candidate which has possible problematic function partially or fully removed. The “neutered” version of the virus can be tested in a lab and in clinical trials for efficacy. This patent covers a vaccine candidate utilizing computationally reducible fragments related to Civet SARS, Bat Sars, and BtRs and BtRI BetaCov; those fragments removed from future Covid-19 Super Organisms either collectively (as in this patent) or individually; as well as the RNA transcripts of those fragments.

Abstract: A system for the rapid development of vaccines or anti-bacterial drugs is required when working with pandemics. The easiest way to formulate these new vaccines is through computational reduction of existing organisms via statistical models. Once vaccine candidates are arrived at through this method, “Super Organisms” containing all of the computationally reducible fragments can then be taken through a Crispr reduction process wherein those computationally reducible fragments are removed. The result is a vaccine candidate which has possible problematic function partially or fully removed. The “neutered” version of the virus can be tested in a lab and in clinical trials for efficacy. This patent covers a vaccine candidate utilizing computationally reducible fragments 75 to 99 base pairs in length; those fragments removed from future Covid-19 Super Organisms either collectively (as in this patent) or individually; as well as the RNA transcripts of those fragments.

Abstract: A system for the rapid development of vaccines or anti-bacterial drugs is required when working with pandemics. The easiest way to formulate these new vaccines is through computational reduction of existing organisms via statistical models. Once vaccine candidates are arrived at through this method, “Super Organisms” containing all of the computationally reducible fragments can then be taken through a Crispr reduction process wherein those computationally reducible fragments are removed. The result is a vaccine candidate which has possible problematic function partially or fully removed. The “neutered” version of the virus can be tested in a lab and in clinical trials for efficacy. This patent covers a vaccine candidate utilizing computationally reducible fragments 100 base pairs or greater in length; those fragments removed from future Covid-19 Super Organisms either collectively (as in this patent) or individually; as well as the RNA transcripts of those fragments.

Abstract: Modifying existing commercial jet engine technology to leverage the temperature and pressure available in the combustion of kerosene A-1 jet fuel (or other fuels) to include the Haber process (or other industrial processes requiring high temperatures and high pressures) presents possibilities for the creation of ammonia and other down-stream compounds suitable for atmospheric seeding of reflective or absorptive compounds. Compounds such as ammonia and urea (or other compounds—as time goes on) provide alternatives to high-altitude (20 km) seeding of sulfur dioxide (which is destructive to atmosphere, vegetation, and ozone alike).

Abstract: Modifying existing commercial jet engine technology to leverage the temperature and pressure available in the combustion of kerosene A-1 jet fuel (or other fuels) to include the Haber process (or other industrial processes requiring high temperatures and high pressures) presents possibilities for the creation of ammonia and other down-stream compounds suitable for atmospheric seeding of reflective or absorptive compounds to reduce global temperatures. Compounds such as ammonia (to start) and urea (or other compounds—as time goes on) provide alternatives to Smith and Wegner's proposal of high-altitude (20 km) seeding of sulfur dioxide (which is destructive to atmosphere, vegetation, and ozone alike).